Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluocinolone Acetonide Clear all
Completed Phase 4 Interventional

Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma

NCT00469183
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Los Angeles, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 4 Interventional

Phase 4 IOP Signals Associated With ILUVIEN®

NCT02424019
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
ILUVIEN 0.19 MG
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

NCT01469767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide cream
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Not applicable Interventional

Retisert and Cataract Surgery in Patients With Severe Uveitis

NCT00570830
View directory record Official record
Conditions
Intermediate Uveitis, Posterior Uveitis
Interventions
Retisert (fluocinolone acetonide implant)
Device
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 1 Interventional

Fluocinolone Implant to Treat Macular Degeneration

NCT00008515
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Fluocinolone
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 11:19 AM EDT
Not listed Phase 4 Interventional

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

NCT05322070
View directory record Official record
Conditions
Uveitis, Posterior
Interventions
Fluocinolone Acetonide Intravitreal Implant 0.18 mg
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Fullerton, California • Glendale, California • Pasadena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

NCT01304706
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Alpharetta, Georgia
Source: ClinicalTrials.gov public record
Updated May 3, 2015 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

NCT00472966
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 4, 2026, 11:19 AM EDT
Terminated Phase 4 Interventional Results available

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

NCT00669071
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, Cetaphil® Moisturizing Cream as Inactive Control
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
La Jolla, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 4, 2026, 11:19 AM EDT
Active, not recruiting Early Phase 1 Interventional

A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery

NCT04918121
View directory record Official record
Conditions
Glaucoma
Interventions
Yutiq 0.18 MG Drug Implant
Drug
Lead sponsor
Sanjay Asrani
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 4, 2026, 11:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

NCT03145025
View directory record Official record
Conditions
Uveitis, Posterior
Interventions
Retisert, Fluocinolone Acetonide Intravitreal Implant
Device · Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

NCT00490815
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis

NCT01049243
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide Cream 0.1%
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis

NCT02748512
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment

NCT00543296
View directory record Official record
Conditions
Uveitis
Interventions
0.59 mg Fluocinolone Acetonide implant
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Sep 4, 2026, 11:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

NCT06536491
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
EC-104 high dose, EC-104 low dose, Dexamethasone intravitreal implant
Drug
Lead sponsor
Eclipse Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 4, 2026, 11:19 AM EDT
Completed No phase listed Observational

Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant

NCT04340505
View directory record Official record
Conditions
Uveitis
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 4, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib-induced Hand- Foot Skin Reaction Treatment

NCT00667589
View directory record Official record
Conditions
Hand-foot Skin Reaction, Rash
Interventions
urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, bland emollient cream (Udderly smooth® Udder Cream)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

VANOS Cream and Skin Barrier Function

NCT00819507
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

NCT01694186
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI insert, Sham injection
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 4, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

NCT03345914
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 4, 2026, 11:19 AM EDT
Active, not recruiting Phase 4 Interventional

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

NCT04469595
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Iluvien 0.19 MG Drug Implant, Aflibercept
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 4, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional Results available

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

NCT00770770
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 4, 2026, 11:19 AM EDT